NPH insulin

NPH insulin
	A vial of NPH insulin with insulin syringe
Clinical data
Trade names	Novolin N, Humulin N, Insulatard, others
Other names	Neutral protamine Hagedorn insulin,; protamine zinc insulin (slightly different),; isophane insulin,; compound insulin zinc suspension (slightly different),; intermediate-acting insulin
AHFS/Drugs.com	Monograph
MedlinePlus	a682611
Routes of; administration	Subcutaneous
ATC code	A10AC (WHO) ;
Legal status
Legal status	US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Onset of action	90 minutes
Duration of action	24 hours
Identifiers
CAS Number	53027-39-7;
ChemSpider	none;

Neutral Protamine Hagedorn (NPH) insulin, also known as isophane insulin, is an intermediate-acting insulin given to help control blood sugar levels in people with diabetes.^[3] It is used by injection under the skin once to twice a day.^[1] Onset of effects is typically in 90 minutes and they last for 24 hours.^[3] Versions are available that come premixed with a short-acting insulin, such as regular insulin.^[2]

The common side effect is low blood sugar.^[3] Other side effects may include pain or skin changes at the sites of injection, low blood potassium, and allergic reactions.^[3] Use during pregnancy is relatively safe for the baby.^[3] NPH insulin is made by mixing regular insulin and protamine in exact proportions with zinc and phenol such that a neutral-pH is maintained and crystals form.^[1] There are human and pig insulin based versions.^[1]

Protamine insulin was first created in 1936 and NPH insulin in 1946.^[1] It is on the World Health Organization's List of Essential Medicines.^[4] NPH is an abbreviation for "neutral protamine Hagedorn".^[1]

Medical uses[]

NPH insulin is cloudy and has an onset of 1–4 hours. Its peak is 6–10 hours and its duration is about 10–16 hours.

It has an intermediate duration of action, meaning longer than that of regular and rapid-acting insulin, and shorter than long acting insulins (ultralente, glargine or detemir).

History[]

Hans Christian Hagedorn (1888–1971) and August Krogh (1874–1949) obtained the rights for insulin from Banting and Best in Toronto, Canada. In 1923 they formed Nordisk Insulin laboratorium, and in 1926 with August Kongsted he obtained a Danish Royal Charter as a non-profit foundation.

In 1936, Hagedorn and B. Norman Jensen discovered that the effects of injected insulin could be prolonged by the addition of protamine obtained from the "milt" or semen of river trout. The insulin would be added to the protamine, but the solution would have to be brought to pH 7 for injection. University of Toronto, Canada later licensed protamine zinc insulin (PZI),^[5] to several manufacturers. This mixture only needs to be shaken before injection. The effects of PZI lasted for 24–36 h.

In 1946, Nordisk was able to form crystals of protamine and insulin and marketed it in 1950, as neutral protamine Hagedorn (NPH) insulin. NPH insulin has the advantage that it can be mixed with an insulin that has a faster onset to complement its longer lasting action.^{[medical citation needed]}

Eventually all animal insulins made by Novo Nordisk were replaced by synthetic, recombinant 'human' insulin.^{[medical citation needed]} Synthetic 'human' insulin is also complexed with protamine to form NPH.^{[medical citation needed]}

Timeline[]

1926 Nordisk receives Danish charter to produce insulin
1936 Hagedorn discovers that adding protamine to insulin prolongs the effect of insulin
1936 Canadians D.M. Scott and A.M. Fisher formulate zinc insulin mixture and license to Novo
1946 Nordisk crystallizes a protamine and insulin mixture
1950 Nordisk markets NPH insulin
1953 Nordisk markets "Lente" zinc insulin mixtures.

Society and culture[]

Names[]

NPH stands for neutral protamine Hagedorn, and the words refer to neutral pH (pH = 7), protamine (a protein), and Hans Christian Hagedorn (an insulin researcher).

Brand names include Humulin N, Novolin N, Novolin NPH, Gensulin N, SciLin N, Insulatard, and NPH Iletin II.

References[]

^ Jump up to: ^a ^b ^c ^d ^e ^f Owens, D. R. (1986). Human Insulin: Clinical Pharmacological Studies in Normal Man. Springer Science & Business Media. pp. 134–136. ISBN 9789400941618. Archived from the original on 2017-01-18.
^ Jump up to: ^a ^b ^c ^d British national formulary: BNF 69 (69 ed.). British Medical Association. 2015. pp. 464–472. ISBN 9780857111562.
^ Jump up to: ^a ^b ^c ^d ^e ^f ^g "Insulin Human". The American Society of Health-System Pharmacists. Archived from the original on 22 October 2016. Retrieved 8 January 2017.
^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^ "The History of Insulin" (PDF). Karger.com/. Basel, Switzerland: Karger Publishers. Archived from the original (PDF) on March 4, 2016. Retrieved June 10, 2015.

[Ow1986-1] Jump up to: ^a ^b ^c ^d ^e ^f Owens, D. R. (1986). Human Insulin: Clinical Pharmacological Studies in Normal Man. Springer Science & Business Media. pp. 134–136. ISBN 9789400941618. Archived from the original on 2017-01-18.

[BNF69-2] Jump up to: ^a ^b ^c ^d British national formulary: BNF 69 (69 ed.). British Medical Association. 2015. pp. 464–472. ISBN 9780857111562.

[AHFS2017-3] Jump up to: ^a ^b ^c ^d ^e ^f ^g "Insulin Human". The American Society of Health-System Pharmacists. Archived from the original on 22 October 2016. Retrieved 8 January 2017.

[WHO21st-4] World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[5] "The History of Insulin" (PDF). Karger.com/. Basel, Switzerland: Karger Publishers. Archived from the original (PDF) on March 4, 2016. Retrieved June 10, 2015.

[1]

[2]

[3]

[4]

[5]